Objective: Inhibition of the mammalian target of rapamycin (mTOR) pathway reduces epileptogenesis in various epilepsy models, possibly by inhibition of inflammatory processes, which may include the proteasome system. To study the role of mTOR inhibition in the regulation of the proteasome system, we investigated (immuno) proteasome expression during epileptogenesis, as well as the effects of the mTOR inhibitor rapamycin. Methods: The expression of constitutive (b1, b5) and immunoproteasome (b1i, b5i) subunits was investigated during epileptogenesis using immunohistochemistry in the electrical post-status epilepticus (SE) rat model for temporal lobe epilepsy (TLE). The effect of rapamycin was studied on (immuno)proteasome subunit expression in post-SE rats that were treated for 6 weeks. (Immuno)proteasome expression was validated in the brain tissue of patients who had SE or drug-resistant TLE and the effect of rapamycin was studied in primary human astrocyte cultures. Results: In post-SE rats, increased (immuno)proteasome expression was detected throughout epileptogenesis in neurons and astrocytes within the hippocampus and piriform cortex and was most evident in rats that developed a progressive form of epilepsy. Rapamycin-treated post-SE rats had reduced (immuno)proteasome protein expression and a lower number of spontaneous seizures compared to vehicle-treated rats. (Immuno)proteasome expression was also increased in neurons and astrocytes within the human hippocampus after SE and in patients with drug-resistant TLE. In vitro studies using cultured human astrocytes showed that interleukin (IL)-1b-induced (immuno)proteasome gene expression could be attenuated by rapamycin. Significance: Because dysregulation of the (immuno)proteasome system is observed before the occurrence of spontaneous seizures in rats, is associated with progression of epilepsy, and can be modulated via the mTOR pathway, it may represent an interesting novel target for drug treatment in epilepsy.
Temporal lobe epilepsy (TLE), one the most common forms of epilepsy in adults, is characterized by recurrent seizures and often associated with neuropsychological dysfunction. In about 30-40% of the people with epilepsy, seizures cannot be adequately controlled by antiepileptic drug (AED) treatment. This is a major problem, and therefore novel therapeutic strategies are needed. Targeting brain inflammation may be one of the novel strategies, since clinical and experimental findings support a key role of specific immune and inflammatory processes in epileptogenesis and chronic seizures in drug-resistant TLE. 1 In this respect, the proteasome system is of interest, since it is a major proteolytic system in the cell that is responsible for the degradation of most intracellular proteins and plays a critical role in homeostasis and immunity. 2 In addition to targeting misfolded proteins arising from mutations or damaging metabolic events, the proteasome also plays an important role in the generation of peptides presented by the major histocompatibility complex class I (MHC-I) molecules. 3 The proteasome consists of a barrel-shaped core particle in combination with two possible regulatory particles. 4, 5 The core particle, also known as the 20S core complex, consists of four heptameric rings positioned in an abba-stoichiometry. The ability for catalytic activity resides within the 20S core and depends on the b1, b2, and b5 subunits, which show caspase-, trypsin-and chymotrypsin-like activities, respectively. 6 Under inflammatory conditions, the three constitutive subunits can be replaced by their inducible counterparts (b1i, b2i, and b5i) forming the immunoproteasome. 7, 8 This modified proteasome performs its proteolytic functions more efficiently than the constitutive proteasome, 9 and has been suggested to play a role in epilepsy. 10, 11 However, the changes in expression of the (immuno)proteasome during the development and progression of epilepsy are, to the best of our knowledge, not studied.
A recent study showed that inhibition of the immunoproteasome subunit b5i-reduced epileptiform activity in vitro, 11 and the authors proposed that this is a promising target for therapeutic intervention for reducing seizures that are not controlled by classical AEDs. However, specific immunoproteasome inhibitors (e.g., ONX-0914) penetrate the brain poorly. 12 Several studies show that inhibition of the mammalian target of rapamycin (mTOR) pathway reduces epileptogenesis and/or ictogenesis in various epilepsy models (for review see Ref. 13 ) possibly by restoring blood-brain barrier function and inhibition of various inflammatory processes, 14 which may also include the (immuno)proteasome. The latter is confirmed by a recent study in which the mTOR inhibitor rapamycin was administered after myocardial infarction and reduced (immuno)proteasome expression and activity at the border zone of the infarct. 15 Considering the significant effects of (immuno) proteasome inhibition on seizure activity, 11 rapamycin may also exert effects on the (immuno)proteasome expression in brain and inhibit epileptogenesis and/or ictogenesis. To study this, we investigated the effects of rapamycin on (immuno)proteasome expression in post-status epilepticus (SE) rats during different phases of epileptogenesis. The expression of constitutive and immunoproteasome subunits was studied using immunohistochemistry during the acute, latent, and chronic phase in this model. The expression of (immuno)proteasome subunits was validated in hippocampal autopsy material of patients that died after SE and in resected hippocampal tissue of a large cohort of patients with drug-resistant TLE (with and without hippocampal sclerosis). Furthermore, we investigated the effects of rapamycin in vitro in primary human fetal astrocyte cultures under inflammatory conditions.
Methods

Animals
Adult male Sprague Dawley rats (ordered at 250 g, about 2 months of age), Harlan Netherlands, Horst, The Netherlands) were used in this study, which was approved by the University Animal Welfare committee. The rats were housed individually in a controlled environment (21 AE 1°C; humidity 60%; lights on 08:00 a.m. to 8:00 p.m.; food and water available ad libitum). See Data S1 for electrode implantation, SE induction, electroencephalography (EEG) monitoring, and perfusion and Figure S2 for the individual seizure frequency.
Rapamycin treatment
One group of the rats was treated with the immunosuppressant rapamycin as described previously. 16 Briefly, rapamycin was administered intraperitoneally (6 mg/kg/day) under isoflurane anesthesia starting 4 h after SE. Rapamycin was given daily for 7 days, after which administration Key Points • In the post-SE rat TLE model, (immuno)proteasome subunit expression increased during the acute, latent, and chronic phases
• In post-SE rats, overexpression of (immuno)proteasome subunits was most evident in rats with a progressive development of epilepsy
• Rapamycin treatment reduced b5 and b5i expression in post-SE rats, which was associated with a reduced seizure frequency
• (Immuno)proteasome subunit expression increased in human hippocampus of patients with SE or TLE
• Rapamycin attenuated IL-1b-induced (immuno)proteasome subunit overexpression in human fetal astrocytes changed to every other day until the rats were sacrificed at 6 weeks post-SE (n = 7). In addition, vehicle-treated post-SE rats (n = 8) and rapamycin-treated controls (n = 6) were included.
Human subjects
The cases included in this study were obtained from the archives of the departments of pathology of the Academic Medical Center (AMC, Amsterdam, The Netherlands) and the VU University medical center (VUmc, Amsterdam, The Netherlands). A total of 37 hippocampal specimens, removed from patients undergoing surgery for drug-resistant TLE, were examined. Tissue was obtained and used in accordance with the Declaration of Helsinki and the AMC Research Code provided by the Medical Ethics Committee. All cases were reviewed independently by two neuropathologists, and the classification of hippocampal sclerosis was based on analysis of microscopic examination as described by the International League Against Epilepsy (ILAE). 17 Control material was obtained during autopsy of age-matched individuals. Resected hippocampal tissue of 20 patients with hippocampal sclerosis (HS) and 15 patients without HS (non-HS) was used. In addition, autopsy material of six patients who died after SE and seven age-matched controls without a history of seizures or other neurologic diseases was used. SE arose de novo, and pathologic examination excluded structural abnormalities in the brain, as well as encephalitis or meningitis. Table S1 summarizes the clinical characteristics of the patients and controls.
Immunohistochemistry
Human and rat brain tissue was stained for immunohistochemistry using antibodies against b1, b5, b1i, and b5, as well as phosphorylated-S6 (pS6; as read-out for mTOR activity). For details see Data S1.
Evaluation of immunohistochemistry
Immunoreactivity was evaluated in neurons and astrocytes within the human and rat dentate gyrus (DG) and CA1 by semiquantitative analysis as described previously. 18 For the rat, immunoreactivity was also determined in the piriform cortex, in which usually extensive inflammation and neuronal loss occurs. The intensity of the staining was evaluated using a scale of 0-3 (0, no; 1, weak; 2, moderate; and 3, strong staining). The score represents the predominant cell staining intensity found in each case. In addition, the frequency of b1, b1i, b5, or b5i-positive cells (1, single to 10%; 2, 11-50%; 3, >50%) was also evaluated to give information about the relative number of positive cells. The immunoreactivity score (IRS) was calculated by multiplying the intensity score by the frequency score. The analysis was performed by an experimenter blinded to the group assignments.
Cell cultures
Primary fetal astrocyte-enriched cell cultures were obtained from human fetal brain tissue (14-19 weeks of gestation) obtained from medically induced abortions. All material has been collected from donors from whom written informed consent for the use of the material for research purposes had been obtained by the Bloemenhove clinic (these informed consents are kept together with the medical record of the donor by the clinic). Tissue was obtained in accordance with the Declaration of Helsinki and the AMC Research Code provided by the Medical Ethics Committee of the AMC. Cell isolation was performed as described elsewhere. 18 Briefly, after removal of blood vessels, tissue was mechanically minced into smaller fragments and enzymatically digested by incubating at 37°C for 30 min with 2.5% trypsin (Sigma-Aldrich; St. Louis, MO, USA). Tissue was washed with incubation medium-containing Dulbecco's modified Eagle's medium (DMEM)/HAM F10 (1:1) medium (Gibco/Life Technologies, New York, NY, USA), supplemented with 50 units/ml penicillin, 50 lg/ ml streptomycin, and 10% fetal calf serum (FCS; Gibco/ Life Technologies) and triturated by passing through a 70 lm mesh filter. Cell suspension was incubated at 37°C, 5% CO 2 for 48 h to allow glial cells to adhere to the culture flask before it was washed with phosphatebuffered saline (PBS) to remove excess of myelin and cell debris. Cultures were subsequently refreshed twice a week. Cultures reached confluence after 2-3 weeks. Secondary astrocyte cultures for experimental manipulation were established by trypsinizing confluent cultures and subplating onto poly-L-lysine (PLL; 15 lg/ml, SigmaAldrich) precoated 6-and 12-well plates (Costar, Cambridge, MA, USA; 1 9 10 5 cells/well in a 6-well plate for protein isolation and Western blot, 5 9 10 4 cells/well in a 12-well plate for RNA isolation and polymerase chain reaction (PCR). Astrocytes were used at passage 2-4.
Cell cultures were stimulated with human recombinant (r)IL-1b (Peprotech, Rocky Hill, NJ, USA; 10 ng/ml) for 24 h (n = 5 wells per condition). Treatment of astrocytes with 100 nM rapamycin in 0.05% dimethyl sulfoxide (DMSO; n = 6 wells per condition from a total of three donors) was either started 24 h before, and continued during IL-1b stimulation (pretreatment), or given simultaneously with IL-1b stimulation (simultaneous treatment). Cells were harvested 24 h after stimulation. Viability of human cell cultures was not influenced by the performed treatments (as determined with flow cytometric analysis using Fixable Viability Dye eFluor 780, eBioscience, San Diego, CA, USA).
18 pS6 expression (as read-out for mTOR activity) was studied using Western blot analysis (n = 2 wells per condition from a total of two donors); for details see Data S1.
RNA isolation and real-time quantitative PCR analysis
For RNA isolation, cell culture material was homogenized in Qiazol Lysis Reagent (Qiagen Benelux, Venlo, The Netherlands). Total RNA was isolated using the miRNeasy Mini kit (Qiagen Benelux) according to manufacturer's instructions. The concentration and purity of RNA were determined at 260/280 nm using a Nanodrop spectrophotometer (Ocean Optics, Dunedin, FL, USA). To evaluate b1, b1i, b5, or b5i mRNA expression, 200 ng of cell culture-derived total RNA was reverse-transcribed into complementary DNA (cDNA) using oligo(dT) primers. PCRs were run on a Roche Lightcycler 480 thermocycler (Roche Applied Science, Basel, Switzerland) using the following primers: b1 (forward: ACCAGCTCGGTTTCC ACA, reverse: CCCGGTATCGGTAACACATC); b5 (forward: GAGTCTCAGTGATGGTCTGAGC, reverse: ACT CCATGGCGGAACTTG); b1i (forward: ACCAACCGGG GACTTACC, reverse: TCAAACACTCGGTTCACCAC); b5i (forward: CCCTACCCACCCCTGTTT, reverse: CAC CCAGGGACTGGAAGA). Quantification of data was performed using the computer program LinRegPCR in which linear regression on the Log (fluorescence) per cycle number data is applied to determine the amplification efficiency per sample. 19, 20 The starting concentration of each specific product was divided by the geometric mean of the starting concentrations of reference genes (EF1a and C1orf43), and this ratio was compared between groups.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 22. Multiple groups were compared using the Kruskal-Wallis test. For comparison between two conditions the Mann-Whitney U-test was used. Correlations were assessed using the Kendall's tau correlation test. For cell culture data, statistical analyses were performed with GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA) using nonparametric statistical testing (Mann-Whitney U-test). A value of p < 0.05 was assumed to indicate a statistical difference.
Results
Expression of constitutive subunits b1 and b5 in rat brain Expression of constitutive proteasome subunits was investigated in the DG and CA1 of the rat hippocampus and in the piriform cortex. Expression of b1 and b5 was minimal to weak in the hippocampus of controls (Figs S3A and S4A; Table 1 ). The IRS of b1 was higher in latent (1 week after SE) and chronic phases (7 months after SE) compared to controls in the hippocampus and in the piriform cortex ( Fig. S3C-E ; Table 1 ). The IRS of b5 was higher in both neurons and astrocytes during the acute phase (1 day after SE) as well as in neurons within the DG during the latent phase ( Fig. S4B,C ; Table 1 ). Higher b5 IRS was evident 6 (6-9) 1 6 (3-6) 1 6 (6-9) 1 Latent 9 (6-9)* 6 (4-6)** 9 (6-9)* 6 (4-6)** 9** 6 (4-6)** Chronic p 9** 6** 9* 6* 9** 6* Chronic np 9 (6-9)* 6 (4-6)** 9 (6-9)** 6 (4-6)** 9** 6 (4-6)** b1i during the chronic phase in the DG, CA1, and piriform cortex compared to controls ( Fig. S4D,E ; Table 1 ). Of interest, the IRS was higher in the chronic progressive group as compared to the chronic nonprogressive group in neurons and astrocytes (Table 1) of the piriform cortex.
Expression of immunoproteasome subunits b1i and b5i in rat brain Both inducible subunits b1i and b5i showed no to weak expression in controls (Figs 1A and 2A) . The b1i IRS was higher compared to controls during the acute and latent phase, mainly in dendrites of CA1 pyramidal cells, DG granule cells, and neurons within the piriform cortex (Fig. 1B,C, Table 1 ). During the chronic phase, a higher IRS of b1i compared to controls was also observed in dendrites and somata of neurons within the DG, CA1, and piriform cortex as compared to controls ( Fig. 1D,E ; Table 1 ). During this phase, the IRS was higher in neurons of the DG and in neurons and astrocytes of the piriform cortex ( Table 1 ) of rats that developed a progressive form of epilepsy as compared to rats that developed a nonprogressive form of epilepsy. The b5i IRS was higher compared to controls in astrocytes within the DG during both acute and latent phases together with the piriform cortex during the latent phase ( Fig. 2B,C ; Table 1 ). During the chronic phase, b5i IRS was higher in the DG, CA1, and piriform cortex for rats that developed a progressive form of epilepsy compared to controls ( Fig. 2E ; Table 1 ). In nonprogressive rats, the b5i IRS was higher in astrocytes within the DG and neurons of the piriform cortex compared to controls ( Fig. 2D ; Table 1 ). Of interest, the IRS for b5i was higher in the progressive group compared to the nonprogressive group.
(Immuno)proteasome subunit expression in rat brain and seizure frequency A positive correlation between the IRS and the number of seizures in the week before the animals were killed was observed in b5 positive neurons of the DG (s = 0.55, p < 0.05) and in astrocytes within the CA1 for both b5 (s = 0.73, p < 0.05) and b5i (s = 0.83, p = 0.01). Strong correlations between seizure frequency and subunit b1i and b5 were found in the piriform cortex in both neurons (s = 0.78, p < 0.05, s = 0.68, p < 0.05, respectively) and astrocytes (s = 0.78, p < 0.05, s = 0.80, p < 0.01, respectively). A positive correlation was also found between b5i IRS in astrocytes within the piriform cortex and seizure frequency (s = 0.58, p < 0.05).
Expression of constitutive subunits b1 and b5 in human hippocampus
Resected brain tissue was used from 20 patients with TLE with hippocampal sclerosis (HS group) and 17 patients without HS (non-HS group). In addition, autopsy brain tissue from patients who died after SE (n = 6) and autopsy control tissue (n = 7) was used. The clinical features of the cases are summarized in Table S1 . There were no differences in age between the four groups, and neither was there a difference in duration of epilepsy, age of onset of epilepsy, or seizure frequency between the HS and non-HS groups.
Weak expression of the constitutive subunits b1 was observed in the cytoplasm of neurons within the DG and CA1 of control tissue (Fig. S5A,B) , whereas staining in astrocytes was absent. Constitutive subunit b5 was weakly expressed in the nucleus and cytoplasm of some neurons and astrocytes within the DG and CA1 of control tissue (Fig. S6A,B) . After SE, the expression of b5 increased in neurons within the DG (Fig. S6F) and CA1 (Fig. S6E and Table S2 ) compared to controls. In non-HS, the IRS of b1 and b5 was higher in neurons and astrocytes as compared to controls, but this was most evident in the nucleus and cytoplasm of neurons and astrocytes within the HS-group (Figs. S5C,D,G,H; S6C,D,G,H; Table S2 ).
Expression of immunoproteasome subunits b1i and b5i in human hippocampus
Immunoproteasome subunits b1i and b5i showed no to weak expression in the DG (Figs 3B and 4B) and CA1 ( Figs 3A and 4A ) of controls. The b1i IRS was higher in astrocytes within the DG and CA1 after SE (Fig. 3E,F ) compared to controls (Table S2 ). The b1i and b5i IRS was higher in patients with TLE (Figs 3C,D,G,H; 4C,D,G,H; Table S2 ) as compared to controls, and was most evident in neurons and astrocytes of patients with HS.
Spontaneous seizure frequency and expression (immuno)proteasome subunits in hippocampus of rapamycin-treated rats
To investigate the effect of rapamycin on seizure activity and (immuno)proteasome subunit expression, post-SE rats were treated for 6 weeks. The expression of pS6, (the downstream target of mTOR) was lower in rapamycin-treated post-SE rats (Fig. S7C ) as compared to vehicle-treated post-SE rats (Fig. S7B) and was comparable to control rats (Fig. S7A) , indicating that the mTOR pathway was properly inhibited.
The seizure frequency of rapamycin-treated post-SE rats was lower compared to vehicle-treated post-SE rats (0.12 AE 0.09 seizures per day vs. 8.30 AE 2.45 seizures per day during the week before they were sacrificed).
The IRS of both subunits b5 and b5i was lower in neurons within the DG and CA1 of post-SE rats treated with rapamycin compared to rats that received vehicle (Table 2) . Furthermore, the IRS of b1 in DG neurons, b1i in DG, and CA1 neurons and astrocytes, and b5i in DG and CA1 astrocytes in rapamycin-treated rats was not different from controls, whereas the IRS of vehicle-treated rats was increased in those areas as compared to controls ( Table 2) .
Modulation of (immuno)proteasome expression in human fetal astrocytes
Because we observed reduced immunoproteasome expression in rapamycin-treated rats we studied the modulation in more detail in an in vitro system. We therefore investigated the effect of rapamycin on (immuno)proteasome expression under inflammatory conditions in human fetal astrocytes. Stimulation with IL-1b increased Expression of immunoproteasome b1i subunit in rat hippocampus and piriform cortex. Increased expression of b1i was observed, mainly in dendrites within the hippocampus and piriform cortex, during the acute (B; n = 5), latent (C; n = 6), and chronic phase (D, E) compared to controls (A; n = 5). During the chronic phase, increased expression of b1i was particularly evident in rats that developed a progressive form of epilepsy (E; n = 6) as compared to rats that developed a nonprogressive form of epilepsy (D; n = 5), or controls. Insets in C depict expression of subunit b1i (green) in astrocytes (glial fibrillary acidic protein [GFAP]-positive, red) and occasionally in activated microglia (IBA-1-positive, red). Pcl, pyramidal cell layer; sr, stratum radiatum; slm, stratum lacunosum moleculare; ml, molecular layer; gcl, granular cell layer. Arrows indicate positive cells with neuronal morphology; arrowheads indicate positive dendritic staining. Scale bar hippocampus: 500 lm; CA1, DG, piriform: 50 lm; insets: 25 lm. Epilepsia ILAE expression of the inducible subunits b1i and b5i, but not of the b1 and b5 subunits (Fig. S8A) . When rapamycin was added to these cultures, we confirmed proper inhibition of the mTOR pathway by Western blot analysis, since the expression of pS6 was reduced when cells were pretreated with rapamycin or when rapamycin was added simultaneously with IL-1b (Fig. S8B) . The IL-1b-induced expression of b1i and b5i could be decreased when cells were Expression of immunoproteasome b5i subunit in rat hippocampus and piriform cortex. b5i expression is higher in astrocytes within the hippocampus and piriform cortex, during acute (B; n = 5), latent (C; n = 6), and chronic phases (D, E) compared to controls (A; n = 5). During the chronic phase, increased expression of b5i was particularly evident in neurons and astrocytes of rats that developed a progressive form of epilepsy (E; n = 6), as compared to rats that developed a nonprogressive form of epilepsy (D; n = 5) or controls (A). Insets in C depict expression of subunit b1i (green) in astrocytes (GFAP-positive, red) and occasionally in activated microglia (IBA-1-positive, red). Pcl, pyramidal cell layer; sr, stratum radiatum; slm, stratum lacunosum moleculare; ml, molecular layer; gcl, granular cell layer. Arrows indicate positive cells with neuronal morphology; arrowheads indicate positive dendritic staining. Scale bar hippocampus: 500 lm; CA1, DG, piriform: 50 lm; insets: 25 lm. Epilepsia ILAE pretreated with rapamycin and when rapamycin was added simultaneously with IL-1b (Fig. S8C) . Rapamycin pretreatment and simultaneous treatment with IL-1b also decreased expression of the constitutive subunits b1 and b5 (Fig. S8C) .
Discussion
We demonstrated that the expression of (immuno)proteasome subunits was increased in neurons and astrocytes during the acute, latent, and chronic phases of the post-SE rat model. Of interest, the expression of the (immuno)proteasome subunits was most evident in rats with a progressive development of epilepsy. Increased expression of (immuno) proteasome subunits was also evident in neurons and astrocytes within resected hippocampi of patients after SE, as well as in patients with TLE, and was most evident in patients with HS. In vivo, rapamycin reduced the expression of b5 and b5i subunits in the hippocampus of post-SE rats, which was associated with a reduced seizure frequency. In vitro, increased expression of the (immuno)proteasome could be attenuated by rapamycin in IL-1b-stimulated fetal human astrocytes. These findings will be discussed in further detail in the following paragraphs.
Increased expression of (immuno)proteasome subunits in the epileptic rat and human brain
In the post-SE rat model, increased expression of constitutive and immunoproteasome subunits was evident in the hippocampus during the acute phase (one day after SE) and particularly during the latent phase (one week after SE). The latter coincides with the peak of the inflammatory response in this model, when gliosis is maximal [21] [22] [23] [24] and when neuronal loss/cellular stress is most abundant. 25 Of interest, increased expression of constitutive and immunoproteasome subunits was also evident during the chronic phase (7 months after SE), particularly in the piriform cortex of rats that developed a progressive form of epilepsy. This may be explained by the fact that extensive neuronal loss occurs in this brain region and that brain inflammation, gliosis, and disruption of the blood-brain barrier is prominently present during the chronic phase in the piriform cortex of rats with frequent daily seizures. 14, [25] [26] [27] This suggests that dysregulation of the (immuno)proteasome contributes No to weak b5i expression was observed in the CA1 (A) and dentate gyrus (DG; B) of autopsy controls (n = 7), and in the hippocampus of patients with TLE without hippocampal sclerosis (non-HS, n = 15; C and D), as well as in the hippocampus of patients who died after SE (E and F, n = 6). Increased expression was observed in the hippocampus of patients with hippocampal sclerosis in cells with neuronal (arrows), and glial (arrowheads) morphology (HS, n = 20; G, H, I, and J) compared to controls. The insets in I show double labeling of b1i (blue) and NeuN (neurons; red). The inset in J shows double labeling of b1i (blue) and GFAP (astrocytes; red). Scale bar:
A-H, 100 lm; I-J, 50 lm; insets, 12.5 lm. Epilepsia ILAE Table 2 . Immunoreactivity scores of b1, b1i, b5, and b5i proteasome subunits in rat vehicle and rapamycin-treated rats
Increased expression of (immuno)proteasome subunits was also observed in the hippocampus of patients with SE or TLE. Increased expression of immunoproteasome subunits was also found in a previous study, 10 in which a small cohort of TLE patients with HS and/or focal cortical dysplasia was studied. In the present study, we used a large cohort of patients with TLE and discriminated between patients with and without HS. Increased expression of (immuno)proteasome subunits was most evident in patients with HS, suggesting that hippocampal pathology is involved in the regulation of the (immuno)proteasome pathway. Because the immunoproteasome pathway is activated by inflammatory mediators, 28 the higher expression of the immunoproteasome in patients with HS versus patients without HS might be explained by proinflammatory cytokines interferon c (IFNc), tumor necrosis factor a (TNFa), and interleukin (IL)-1b, which are known to be particularly increased in TLE with HS. 29 This is in agreement with our in vitro studies, in which IL-1b stimulation of fetal human astrocytes increased the expression of (immuno)proteasome subunits.
In our previous study, we also observed increased (immuno)proteasome expression in two other epilepsy-associated pathologies in which brain inflammation and activation of the mTOR pathway is evident: focal cortical dysplasia and tuberous sclerosis complex. 18 Glial and neuronal expression positively correlated with seizure frequency in these pathologies, suggesting that increased expression of the (immuno)proteasome can contribute to seizure activity.
Rapamycin reduces (immuno)proteasome expression and the number of spontaneous seizures in post-SE rats Post-SE rats that were treated with rapamycin had a lower expression of subunits b5 and b5i in comparison to vehicle-treated epileptic rats. This was associated with reduced seizure frequency. Pharmacologic inhibition of the mTOR pathway has been shown to suppress seizures in post-SE models, 16, 27, 30 but also in other epilepsy models (for review see Citraro et al.), 13 as well as in a recent phase-3, randomized, double-blind, placebo-controlled study in patients with drug-resistant TSC. 31 However, the exact mechanisms through which mTOR inhibition suppresses seizures is not fully understood. In a recent study, Mishto et al. 11 showed that pharmacologic inhibition of immunoproteasome subunit b5i by ONX-0914 in hippocampal/entorhinal cortex slices of rats 2-3 months post-SE delays or even prevents seizure-like events induced by 4-aminopyridine. This suggests that seizures can be reduced or prevented via inhibition of the immunoproteasome. Modulating proteasome expression by inhibiting proteasome subunits in animal models or with knock-out experiments can provide more insight into the therapeutic potential of modulating the proteasome on the development of epileptic seizures.
Rapamycin modulates (immuno)proteasome expression in human cultured astrocytes
Because we observed reduced immunoproteasome expression in rapamycin-treated rats we studied the modulation in more detail in an in vitro system. Rapamycin reduced expression of both constitutive and inducible subunits in cultured human fetal astrocytes under inflammatory conditions. This is comparable to what we observed in our previous study using astroglial cultures derived from patients with focal cortical dysplasia. 18 Following the success of inhibitors of the constitutive proteasome, which is now an established treatment modality for multiple myeloma, compounds that selectively inhibit the immunoproteasome are currently under active investigation. 9 However, specific immunoproteasome inhibitors (e.g. ONX-0914) penetrate the brain poorly. 12 So, improvement of the bioavailability and blood-brain barrier passage is needed for these compounds to inhibit the immunoproteasome in the brain.
Conclusion
The (immuno)proteasome system is dysregulated in the epileptic rat and human brain. Furthermore, proteasome expression levels can be strongly reduced by mTOR inhibition, suggesting that reduced proteasome activity could be one of the mechanisms by which epilepsy development can be regulated. Because increased expression of the (immuno) proteasome occurs before the occurrence of seizures in rats, is associated with progression of epilepsy, and can be modulated via the mTOR pathway, it may represent an interesting novel target for drug treatment in epilepsy.
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